<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00776399</url>
  </required_header>
  <id_info>
    <org_study_id>2008-993 Mie-U-IRB</org_study_id>
    <nct_id>NCT00776399</nct_id>
  </id_info>
  <brief_title>Radiofrequency Ablation in Resectable Colorectal Lung Metastasis</brief_title>
  <official_title>Radiofrequency Ablation in Resectable Colorectal Lung Metastasis: A Phase-II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mie University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mie University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung metastasectomy is the only therapeutic option to provide a long-survival in patients
      with colorectal lung metastases. Recent studies have shown that radiofrequency (RF) ablation
      is a safe and useful therapeutic option for the treatment of unresectable lung metastases. In
      this phase-II trial, clinical utility of lung RF ablation will be evaluated in patients with
      resectable colorectal lung metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a phase-II clinical trial.

      Lung metastasectomy is the only therapeutic option to provide a long-survival in patients
      with colorectal lung metastases. Recent studies have shown that radiofrequency (RF) ablation
      is a safe and useful therapeutic option for the treatment of unresectable lung metastases. In
      this clinical trial, clinical utility of lung RF ablation will be evaluated.

      Patients with resectable lung metastases will receive lung RF ablation.

      All subjects will be followed for overall survival, safety, change in respiratory function,
      cancer-specific survival, and local tumor progression.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 1, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome Measures:3-year survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome measures:safety, change in respiratory function, cancer-specific survival, and local tumor progression, Radiological studies</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Lung Metastasis</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Lung radiofrequency ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lung radiofrequency ablation</intervention_name>
    <description>A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.</description>
    <arm_group_label>Lung radiofrequency ablation</arm_group_label>
    <other_name>Cool-tip radiofrequency ablation system is used.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary lesions (colorectal cancer) are resected.

          -  Lung metastases appear.

          -  No extrapulmonary metastases or after locoregional treatments.

          -  Lung metastasis is considered to be controllable either by metastasectomy or
             radiofrequency (RF) ablation.

          -  Five or less lung metastases measuring 3cm or smaller.

          -  PET study within 8 weeks before metastasectomy or RF ablation.

          -  White blood count of 3000/mm3 or more.

          -  Platelet count of 100,000/mm3 or more.

          -  Hemoglobin level of 8.0 g/dl.

          -  Serum creatinine level of 2.0 mg/dl or less.

          -  PaO2 of 70 mm Hg or more（Room air）or SpO2 of 93%.

          -  Serum bilirubin level of 2.0 mg/dl or less.

          -  Performance status of 0 or 1.

          -  Expected survival of 1 year or more.

          -  Age of 20 years or more.

          -  Informed consent from the patient.

        Exclusion Criteria:

          -  Risk to injure lung vessels 5 mm or larger.

          -  Lung metastases adjacent to the heart, trachea, esophagus, and aorta.

          -  Association of uncontrollable malignancies.

          -  Lung hilar lymph node metastasis.

          -  One lung.

          -  Pulmonary hypertension.

          -  Coagulopathy.

          -  Impossible to stop using anticoagulants.

          -  Active infection or C-reactive protein of 3 or higher.

          -  Association of active inflammation.

          -  Fever (higher than 38 degrees celsius).

          -  Previous external-beam radiotherapy for the treated lung.

          -  Pregnant.

          -  Judgment to be an inappropriate candidate by a attending physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haruyuki Takaki, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Radiology, Mie University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anjo kosei hospital</name>
      <address>
        <city>Anjo</city>
        <state>Aichi</state>
        <zip>446-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464－8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaidou</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamada red-cross hospital</name>
      <address>
        <city>Ise</city>
        <state>Mie</state>
        <zip>516-0805</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsusaka munipal hospital</name>
      <address>
        <city>Matsusaka</city>
        <state>Mie</state>
        <zip>515-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsusaka central hospital</name>
      <address>
        <city>Matsusaka</city>
        <state>Mie</state>
        <zip>515-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzuka Kaisei Hospital</name>
      <address>
        <city>Suzuka</city>
        <state>Mie</state>
        <zip>513-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzuka central hospital</name>
      <address>
        <city>Suzuka</city>
        <state>Mie</state>
        <zip>513-8630</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toyama hospital</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>514-0043</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mie central medical center</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>514-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mie University</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mie prefectual medical center</name>
      <address>
        <city>Yokkaichi</city>
        <state>Mie</state>
        <zip>510-8561</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University</name>
      <address>
        <city>Kayama</city>
        <state>Okayama</state>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto University</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto Prefectual University of Kyoto</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama Saiseikai Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Yamakado K, Hase S, Matsuoka T, Tanigawa N, Nakatsuka A, Takaki H, Takao M, Inoue Y, Kanazawa S, Inoue Y, Sawada S, Kusunoki M, Takeda K. Radiofrequency ablation for the treatment of unresectable lung metastases in patients with colorectal cancer: a multicenter study in Japan. J Vasc Interv Radiol. 2007 Mar;18(3):393-8.</citation>
    <PMID>17377185</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2008</study_first_submitted>
  <study_first_submitted_qc>October 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2008</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mie University</investigator_affiliation>
    <investigator_full_name>Koichiro Yamakado</investigator_full_name>
    <investigator_title>instructor of Department of Interventional Radiology</investigator_title>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>lung metastasis</keyword>
  <keyword>radiofrequency ablation</keyword>
  <keyword>metastasectomy</keyword>
  <keyword>Lung metastasis from colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

